Serum Syndecan-1 Levels for 130 HSCT Patients Over 28 Days

130 patients undergoing hematopoietic stem cell transplantation had serial blood samples collected from day 0 through day 28 post-transplant. This prospective study by Takayuki Yokokawa investigated serum Syndecan-1 kinetics as a predictor for early mortality within 100 days. Serum SDC1 levels at Days 0, 14, and 21 were significantly higher in the 12 patients who died compared to survivors.

Use Cases

• Predicting early mortality risk based on longitudinal serum SDC1 levels.
• Identifying patients at high risk for endothelial injury complications like SOS and TA-TMA.
• Validating Syndecan-1 as a biomarker for vascular integrity in transplant recipients.
• Analyzing biomarker kinetics over a 28-day post-transplant period.

Strengths

• Prospective study design with serial measurements from 130 patients.
• Explicitly links biomarker levels to clinical outcomes, with 12 deaths observed.
• Focus on a specific 100-day mortality endpoint with clear time points (Days 0, 14, 21).

Limitations

• Dataset scale is limited to 19.1 KB, suggesting a summary table rather than raw patient-level data.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for machine learning.

Provenance

Source

figshare

Collection Method

Prospective study with serial blood sample collection.

Time Range

Observations from day of HSCT through day 28 post-transplant, with mortality tracked within 100 days.

Freshness

Last updated 2026-05-14 05:47:32; freshness should be verified.